An Observational Study of Tarceva (Erlotinib) in Patients With Non-Small Cell Lung Cancer

NCT ID: NCT01488331

Last Updated: 2016-11-02

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

217 participants

Study Classification

OBSERVATIONAL

Study Start Date

2010-06-30

Study Completion Date

2013-11-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This prospective, multi-center, observational study will assess the progression-free survival and safety of patients with locally advanced or metastatic non-small cell lung cancer treated with Tarceva (erlotinib) and not disease progressing after at least 9 months. Data will be collected for 24 months.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Non-Squamous Non-Small Cell Lung Cancer

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Cohort

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Adult patients, \>/=18 years of age
* Diagnosis of locally advanced or metastatic non-small cell lung cancer (NSCLC, stage III/IV)
* Treatment with Tarceva monotherapy and not progressing after at least 9 months at the date of study start

Exclusion Criteria

* Not agreeing to be followed-up (for a maximum of 24 months)
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Hoffmann-La Roche

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Clinical Trials

Role: STUDY_DIRECTOR

Hoffmann-La Roche

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Abbeville, , France

Site Status

Agen, , France

Site Status

Aix-en-Provence, , France

Site Status

Aix-en-Provence, , France

Site Status

Ajaccio, , France

Site Status

Amiens, , France

Site Status

Angers, , France

Site Status

Annecy, , France

Site Status

Aubagne, , France

Site Status

Auxerre, , France

Site Status

Bastia, , France

Site Status

Bordeaux, , France

Site Status

Bourg-en-Bresse, , France

Site Status

Brest, , France

Site Status

Brest, , France

Site Status

Bron, , France

Site Status

Bry-sur-Marne, , France

Site Status

Caen, , France

Site Status

Cagnes-sur-Mer, , France

Site Status

Chalon-sur-Saône, , France

Site Status

Chambray-lès-Tours, , France

Site Status

Chaumont, , France

Site Status

Chauny, , France

Site Status

Cholet, , France

Site Status

Clamart, , France

Site Status

Clermont-Ferrand, , France

Site Status

Colmar, , France

Site Status

Compiègne, , France

Site Status

Coquelles, , France

Site Status

Cornebarrieu, , France

Site Status

Creil, , France

Site Status

Créteil, , France

Site Status

Dax, , France

Site Status

Dijon, , France

Site Status

Draguignan, , France

Site Status

Eaubonne, , France

Site Status

Fréjus, , France

Site Status

Gap, , France

Site Status

Gleizé, , France

Site Status

Helfaut, , France

Site Status

Hyères, , France

Site Status

La Chaussée-Saint-Victor, , France

Site Status

La Roche-sur-Yon, , France

Site Status

La Rochelle, , France

Site Status

La Source, , France

Site Status

La Tronche, , France

Site Status

Le Plessis-Robinson, , France

Site Status

Libourne, , France

Site Status

Limoges, , France

Site Status

Longjumeau, , France

Site Status

Lyon, , France

Site Status

Lyon, , France

Site Status

Meaux, , France

Site Status

Metz, , France

Site Status

Meudon, , France

Site Status

Montauban, , France

Site Status

Montpellier, , France

Site Status

Mulhouse, , France

Site Status

Nancy, , France

Site Status

Nantes, , France

Site Status

Nevers, , France

Site Status

Paris, , France

Site Status

Paris, , France

Site Status

Paris, , France

Site Status

Perpignan, , France

Site Status

Perpignan, , France

Site Status

Pierre-Bénite, , France

Site Status

Pontoise, , France

Site Status

Reims, , France

Site Status

Reims, , France

Site Status

Rennes, , France

Site Status

Rouen, , France

Site Status

Saint-Aubin-lès-Elbeuf, , France

Site Status

Saint-Avold, , France

Site Status

Saint-Brieuc, , France

Site Status

Saint-Jean, , France

Site Status

Saint-Priest-en-Jarez, , France

Site Status

Saint-Priest-en-Jarez, , France

Site Status

Saint-Quentin, , France

Site Status

Salon-de-Provence, , France

Site Status

Senlis, , France

Site Status

Strasbourg, , France

Site Status

Strasbourg, , France

Site Status

Strasbourg, , France

Site Status

Tarbes, , France

Site Status

Thionville, , France

Site Status

Toulon, , France

Site Status

Toulon, , France

Site Status

Toulouse, , France

Site Status

Tours, , France

Site Status

Vénissieux, , France

Site Status

Vichy, , France

Site Status

Countries

Review the countries where the study has at least one active or historical site.

France

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

ML22973

Identifier Type: -

Identifier Source: org_study_id